Montelukast in pediatric asthma management

Indian Journal of Pediatrics

Volumn 73, Issue 4, 2006, Pages 275-282

  Walia, Mandeep ^a   Lodha, Rakesh ^a   Kabra, S K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Allergic rhinitis; Childhood asthma; Leukotriene antagonists; Montelukast

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CETIRIZINE; CORTICOSTEROID; MONTELUKAST; NITRIC OXIDE; PSEUDOEPHEDRINE; ACETIC ACID DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADD ON THERAPY; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ASTHMA; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; EAR INFECTION; EXERCISE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LOW DRUG DOSE; NAUSEA; PATIENT SATISFACTION; PHARYNGITIS; REVIEW; ADOLESCENT; BRONCHUS DISEASE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HAY FEVER; INFANT; INHALATIONAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; STENOSIS, OCCLUSION AND OBSTRUCTION;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ASTHMA; BRONCHIAL DISEASES; CHILD; CONSTRICTION, PATHOLOGIC; HUMANS; INFANT; LEUKOTRIENE ANTAGONISTS; PRACTICE GUIDELINES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS; RHINITIS, ALLERGIC, SEASONAL;

EID: 33746884316     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02825818     Document Type: Review

References (53)

1. Wright AL, Taussig LM. Lessons from long term cohort studies: childhood asthma. Eur Respir J Suppl 1998; 27: 17S-22S.
2. National Heart Lung and Blood Institute. NAEPP Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma-Update on Selected Topics 2002. downloaded from www.nhlbi.nih.gov/guidelines/asthma/execsumm.
3. Global Strategy for Asthma Management and Prevention. NIH Publication No 02-3659 Issued January, 1995 (updated 2002). Management Segment (Chapter 7): Updated 2004 from the 2003 document. Downloaded from www.ginasthma.org
4. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The antiinflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001; 119: 1533-1546.
5. Sarau HM, Ames RS, Chambers J et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 1999; 56: 657-663.
6. Bisgaard H, Groth S, Madsen F. Bronchial hyperreactivity to leukotriene D4 and histamine in exogenous asthma. Br Med J 1985; 290: 1468-1471.
7. Bisgaard H, Olsson P, Bende M. Effects of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16: 289-297.
8. Spada CS, Nieves AL, Krauss AH-P, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophils and neutrophil motility in vitro . J Leukoc Biol 1994; 55: 183-191.
9. Christie PE, Barnes NC. Leukotriene B4 and asthma. Thorax 1996; 51: 1171-1173.
10. Cheng H, Leff JA, Amin R et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996; 13: 445-448.
11. Knorr B, Larson P, Nguyen HH et al. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol 1999; 39: 786-793.
12. Knorr B, Nguyen HH, Kearns GL et al. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J Clin Pharmacol 2001; 41: 612-619.
13. Zhao JJ, Rogers JD, Holland SD et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 1997; 18: 769-777.
14. Chiba M, Xu X, Nishime JA, Balani SK, Lin JH. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos 1997; 25: 1022-1031.
15. Balani SK, Xu X, Pratha V et al. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos 1997; 25: 1282-1287.
16. Skoner D. Montelukast in 2- to 5-year-old children with asthma. Pediatr Pulmonol Suppl 2001; 21: 46-48.
17. Migoya E, Kearns GL, Hartford A et al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol 2004; 44: 487-494.
18. Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast. Chest 1998; 114: 332-334.
19. Straub DA, Moeller A, Minocchieri S et al. The effect of monte-lukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 2005; 25: 289-294.
20. Bisgaard H, Zielen S, Garcia-Garcia ML et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171 : 315-322.
21. Van Adelsberg J, Moy J, Wei LX et al. Safety, tolerability, and exploratory efficacy of montelukast in 6 to 24 month-old patients with asthma. Curr Med Res & Opin 2005; 21: 971-979.
22. Becker A, Swern A, Tozzi CA, Yu Q, Reiss T, Knorr B. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr Med Res Opin 2004; 20: 1651-1659.
23. Phipatanakul W, Greene C, Downes SJ et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003; 91: 49-54.
24. Strauch E, Moske O, Thoma S et al. A randomized controlled trial on the effect of montelukast on sputum eosinophils cationic protein in children with corticosteroid-dependent asthma. Pediatr Res 2003; 54 : 198-203.
25. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J Allergy Clin Immunol 2002; 109: 257-263.
26. Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA et al. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. J Allergy Clin Immunol 2002; 109: 794-799.
27. Knorr B, Franchi LM, Bisgaard H et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108: E48.
28. Bisgaard H, Nielsen KG. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am J Respir Crit Care Med 2000; 162: 187-190.
29. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999; 160: 1227-1231.
30. Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998; 279: 1181-1186.
31. Stelmach I, Bobrowska-Korzeniowska M, Majak P, Stelmach W, Kuna P. The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma. Pulm Pharmacol Ther 2005; 18: 374-380.
32. Szefler SJ, Phillips BR, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233-242.
33. Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast compared with fluticasone, control of asthma among 6 to 14 year old patients with mild asthma: The MOSAIC study. Pediatrics 2005; 116: 360-369.
34. Karaman O, Sunneli L, Uzuner N et al. Evaluation of montelukast in 8-14 year old children with mild persistent asthma and compared with inhaled corticosteroids. Allergol Immunopathol (Madr) 2004; 32: 21-27.
35. Bukstein DA, Luskin AT, Bernstein A. Real world effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003; 90: 543-549.
36. Buchvald F, Bisgaard H. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. Ann Allergy Asthma Immunol 2003; 91: 309-313.
37. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2005 25; CD003137.
38. Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate phase and late phase responses. J Allergy Clin Immunol 2003; 111: 301-317.
39. Peroni DG, Piacentini GL, Ress M et al. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. Pediatr Allergy Immunol 2002; 13: 434-437.
40. Payaron - Fernandez H , Garcia-Rubia et al. Montelukast administered in the morning or in the evening to prevent exercise induced bronchoconstriction in children. Pediatric Pulmonol 2006; 41: 222-227.
41. Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167: 528-533.
42. Kupczyk M, Kuprys I, Gorski P, Kuna P. The effect of montelukast (10mg daily) and loratadine (10mg daily) on wheal, flare and itching reactions in skin prick tests. Pulm Pharmacol Ther 2006 Mar 2 (In press)
43. Mucha SM, deTineo M, Naclerio RM, Baroody FM. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg 2006; 132 : 164-172.
44. Chen ST, Lu KH, Sun HL, Chang WT, Lue KH, Chou MC. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr. Pediatr Allergy Immunol 2006; 17 : 49-54.
45. Van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 2005; 21 : 971-979.
46. Migoya E, Kearns GL, Hartford A, Zhao J, van Adelsberg J, Tozzi CA, Knorr B, Deutsch P. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol 2004;44 : 487-494.
47. Bisgaard H. Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. J Respir Crit Care Med 2003; 167: 379-383.
48. Peters-Golden M, Henderson WR Jr. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol 2005; 94: 609-618.
49. Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res 2005; 26: 1-5.
50. Stelmach I, Korzeniewska A, Smejda K, Jarosz I, Stelmach W. Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis. Pneumonol Alergol Pol 2004; 72: 85-89.
51. Brandes JL, Visser WH, Farmer MV et al. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. Headache 2004; 44: 581-586.
52. Quack I, Sellin L, Buchner NJ, Theegarten D, Rump LC, Henning BF. Eosinophilic gastroenteritis in a young girl-long term remission under montelukast. BMC Gastroenterol 2005; 18: 24.
53. Lambiase A, Bonini S, Rasi G, Coassin M, Bruscolini A, Bonini S. Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. Arch Ophthalmol 2003; 121: 615-620.